UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.20
-0.25 (-2.18%)
At close: Mar 28, 2025, 4:00 PM
11.35
+0.15 (1.34%)
After-hours: Mar 28, 2025, 5:21 PM EDT
UroGen Pharma Revenue
In the year 2024, UroGen Pharma had annual revenue of $90.40M with 9.29% growth. UroGen Pharma had revenue of $24.57M in the quarter ending December 31, 2024, with 4.40% growth.
Revenue (ttm)
$90.40M
Revenue Growth
+9.29%
P/S Ratio
5.31
Revenue / Employee
$384,672
Employees
235
Market Cap
516.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
URGN News
- 20 days ago - UroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 - Business Wire
- 23 days ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - Business Wire
- 4 weeks ago - UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference - Business Wire
- 5 weeks ago - UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations - Business Wire
- 6 weeks ago - UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire
- 6 weeks ago - Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology - Business Wire